Chardan Capital Upgrades Vyome (NASDAQ:HIND) to Strong-Buy

Vyome (NASDAQ:HIND) was upgraded by equities researchers at Chardan Capital to a “strong-buy” rating in a report released on Thursday, Zacks reports.

HIND has been the topic of several other research reports. Zacks Research raised Vyome to a “hold” rating in a research note on Wednesday, May 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Vyome in a research note on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $9.25.

Vyome Stock Up 2.3%

Shares of HIND opened at $2.23 on Thursday. The company has a 50-day moving average price of $2.18 and a two-hundred day moving average price of $2.28. The stock has a market cap of $15.65 million, a price-to-earnings ratio of -0.66 and a beta of 1.50. Vyome has a 12 month low of $1.75 and a 12 month high of $9.56.

Vyome (NASDAQ:HIND) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.10) earnings per share for the quarter. Vyome had a negative net margin of 3,024.84% and a negative return on equity of 197.33%. The company had revenue of $0.27 million during the quarter. Equities research analysts expect that Vyome will post -0.6 EPS for the current fiscal year.

Institutional Trading of Vyome

A hedge fund recently bought a new position in Vyome stock. Geode Capital Management LLC bought a new position in Vyome Holdings, Inc. (NASDAQ:HIND) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 11,934 shares of the company’s stock, valued at approximately $41,000. Geode Capital Management LLC owned approximately 0.21% of Vyome at the end of the most recent reporting period. Institutional investors and hedge funds own 22.06% of the company’s stock.

Vyome Company Profile

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.